Necessity has spawned innovation in drug development for rare diseases. Thanks to a shift from a product-focused approach to a patient-centered, outcomes-based approach, we are in a critical time of change. Innovative business models must rapidly meet the needs of our new market: the individual patient. This will require more efficient use of resources, transparency across the development and commercial continuum, better and faster access to data, and personalization of the customer experience.
- List lessons learned from orphan drugs development that can be applied to biotech and pharmaceuticals
- Present partnering strategies that help maintain investors’ interest in a tough environment
- Identify steps for developing patient advocacy partnerships that result in faster clinical trial recruitment and drug approval
Ability Level: Advanced
Session ID: 2005